Tolerability and clinical outcome of coseasonal treatment with escherichia coli strain nissle 1917 in grass pollen-allergic subjects

International Archives of Allergy and Immunology

Volumn 163, Issue 1, 2014, Pages 29-35

  Dölle, Sabine ^a   Berg, Jennifer ^a   Rasche, Claudia ^a   Worm, Margitta ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Escherichia coli strain Nissle 1917; Grass pollen allergy; Immunoglobulin A; Rhinoconjunctivitis; Symptom medication score

Indexed keywords

ESCHERICHIA COLI STRAIN NISSLE 1917; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; FEMALE; FLATULENCE; GRASS POLLEN; HUMAN; MALE; MIDDLE AGED; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEASONAL VARIATION; TREATMENT RESPONSE; YOUNG ADULT; CLINICAL ASSESSMENT; DOUBLE BLIND PROCEDURE; IMMUNOMODULATION; PILOT STUDY; PRICK TEST; PROVOCATION TEST; RHINOCONJUNCTIVITIS; SKIN TEST;

ADULT; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PLACEBOS; POLLEN; PROBIOTICS; RHINITIS, ALLERGIC, SEASONAL; SEASONS; SKIN TESTS; TREATMENT OUTCOME;

EID: 84893058201     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000356328     Document Type: Article

References (22)

1. von Mutius E, Braun-Fahrlander C, Schierl R, Riedler J, Ehlermann S, Maisch S, Waser M, Nowak D: Exposure to endotoxin or other bacterial components might protect against the development of atopy. Clin Exp Allergy 2000; 30:1230-1234.
2. Larche M: Regulatory T cells in allergy and asthma. Chest 2007; 132:1007-1014.
3. Matricardi PM, Bjorksten B, Bonini S, Bous-quet J, Djukanovic R, Dreborg S, Gereda J, Malling HJ, Popov T, Raz E, Renz H, Wold A: Microbial products in allergy prevention and therapy. Allergy 2003; 58:461-471. (Pubitemid 36649304)
4. Sonnenborn U, Schulze JT: The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic. Microb Ecol Health Dis 2009; 21:122-158.
5. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A: Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18:45-56. (Pubitemid 36897980)
6. Grozdanov L, Zahringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA, Schombel U, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, Rietschel ET, Dobrindt U: A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysac-charide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 2002; 184:5912-5925. (Pubitemid 35168240)
7. Wohlgemuth S, Loh G, Blaut M: Recent developments and perspectives in the investigation of probiotic effects. Int J Med Microbiol 2010; 300:3-10.
8. Rasche C, Wolfram C, Wahls M, Worm M: Differential immunomodulating effects of inactivated probiotic bacteria on the allergic immune response. Acta Derm Venereol 2007; 87:305-311.
9. Weise C, Zhu Y, Ernst D, Kuhl AA, Worm M: Oral administration of Escherichia coli Nissle 1917 prevents allergen-induced dermatitis in mice. Exp Dermatol 2011; 20:805-809.
10. Cukrowska B, LodInova-ZadnIkova R, Enders C, Sonnenborn U, Schulze J, Tlaskalo-va-Hogenova H: Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 2002; 55:204-209. (Pubitemid 34304560)
11. Magerl M, Lammel V, Siebenhaar F, Zuber-bier T, Metz M, Maurer M: Non-pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells. Exp Derma-tol 2008; 17:427-435. (Pubitemid 351513957)
12. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Pas-salacqua G, Potter P, Valovirta E: Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-324.
13. Juniper EF, Guyatt GH: Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21:77-83.
14. Heine G, Anton K, Henz BM, Worm M: 1alpha, 25-dihydroxyvitamin D3 inhibits an-ti-CD40 plus IL-4-mediated IgE production in vitro. Eur J Immunol 2002; 32:3395-3404. (Pubitemid 36024377)
15. Buters JT, Weichenmeier I, Ochs S, Pusch G, Kreyling W, Boere AJ, Schober W, Behrendt H: The allergen Bet v 1 in fractions of ambient air deviates from birch pollen counts. Allergy 2010; 65:850-858.
16. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498-505. (Pubitemid 32521429)
17. Pfaar O, Barth C, Jaschke C, Hormann K, Klimek L: Sublingual allergen-specific immu-notherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2011; 154:336-344.
18. Demoly P, Calderon MA: Dosing and efficacy in specific immunotherapy. Allergy 2011; 66(suppl 95):38-40.
19. Delcenserie V, Martel D, Lamoureux M, Ami-ot J, Boutin Y, Roy D: Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008; 10:37-54. (Pubitemid 351756577)
20. Stavnezer J: Regulation of antibody production and class switching by TGF-beta. J Immunol 1995; 155:1647-1651.
21. Henker J, Laass MW, Blokhin BM, Maydan-nik VG, Bolbot YK, Elze M, Wolff C, Schrein-er A, Schulze J: Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 2008; 27: 494-499.
22. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beg-linger C, Stolte M, Wolff C, Schulze J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617-1623. (Pubitemid 39434105)